Shenzhen Chipscreen Biosciences Co Ltd. Stock Analysis 688321.SS

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of small molecule drugs. The company is headquartered in Shenzhen, Guangdong and currently employs 1,002 full-time employees. The company went IPO on 2019-08-12. The products primarily include the epigenetic regulator Epidaza (chidamide), the insulin sensitizer Bilessglu (chiglitazar), the triple-pathway tumor inhibitor chiauranib, the small-molecule PD-L1 inhibitor CS23546, the brain-penetrating Aurora B selective inhibitor CS231295 and the highly selective small-molecule allosteric inhibitor CS32582 for tyrosine kinase 2 (TYK2). The firm is also engaged in the development of drugs such as CS1011, CS08399 and CS25141, as well as the licensing of research and development technologies. The firm primarily operates its businesses in the domestic market and overseas markets, including the United States.